Pascale Richetta - UCB SA Insider

UCBJY -- USA Stock  

USD 46.45  0.002  0.0043%

Ms. Pascale Richetta has served as Executive Vice President, Bone Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 1, 2016. She has over 20 years of experience in the pharma and biotech industry. She has acquired commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches. Trained as a medical doctor, Pascale Richetta leads UCBs Bone Patient Value Unit. One of her main missions is to take UCBs investigational osteoporosis drug through the next steps in its development and prepare for its potential launch upon approval. Key positions Prior to UCB, Pascale held the following positions 2013 Present AbbVie Vice President, Western Europe and Canada In charge of a multibillion specialty care portfolio including key biologic products Covering 19 affiliates and over 3000 staff 2004 2013 Abbott Vice President, Western Europe and Canada 1994 2004 GSK Operations Director in France and Europe in charge of the Central Nervous System franchise 19901994 Ipsen Marketing Manager, France 19871990 Product Manager, France. Education 1985 Universite de Poitiers, France M.D. Prior trade association engagement EFPIA Vice Chair of the Executive Committee, member of the Board EBE Member of the Board Europa BIO Member of the Board.
Age: 58  President Since 2016      
32 2 559 99 99

Management Efficiency

The company has return on total asset (ROA) of 7.3 % which means that it generated profit of $7.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.56 % meaning that it generated $15.56 on every $100 dollars invested by stockholders.
The company has accumulated 1.94 B in total debt with debt to equity ratio (D/E) of 28.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.2 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives


Susan AlexanderBiogen
Kathleen WatsonGilead Sciences
George YancopoulosRegeneron Pharmaceuticals
Robert RepellaCSL Limited
Scott SmithCelgene Corporation
Anabella VillalobosBiogen
Laura HamillGilead Sciences
Kasper PoulsenNovo Nordisk AS
Steven HoltzmanBiogen
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
Spyros ArtavanisTsakonasBiogen
Amit SachdevVertex Pharmaceuticals Incorpor
Taiyin YangGilead Sciences
Kenneth PietroBiogen
Kaare SchultzNovo Nordisk AS
Jonathan BillerCelgene Corporation
Alan WillsCSL Limited
Cynthia PattonAmgen
Mark HernonBiogen
Val RombergCSL Limited

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7500 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,500 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Current Sentiment - UCBJY

UCB SA Investor Sentiment

Macroaxis portfolio users are unemotional in their outlook on investing in UCB SA. What is your outlook on investing in UCB SA? Are you bullish or bearish?
50% Bullish
50% Bearish

Also Currentnly Active

Purchased a lot of shares of
few days ago
Traded for 156.0
Purchased a lot of shares of
few days ago
Traded for 156.0
Purchased over 300 shares of
few days ago
Traded for 9.81
Also please take a look at World Market Map. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.